Compare Stocks

Enter up to five stock symbols separated by a comma or space (ex. BAC,WFC,JPM,LON:BARC).

Date Range:

	CRISPR Therapeutics	Neurocrine Biosciences	Acceleron Pharma	Vir Biotechnology	Fate Therapeutics
Symbol	NASDAQ:CRSP	NASDAQ:NBIX	NASDAQ:XLRN	NASDAQ:VIR	NASDAQ:FATE
Price Information
Current Price	$96.17	$104.12	$173.17	$38.79	$60.13
50-Day Moving Average	$117.26	$95.67	$145.04	$45.00	$70.23
52-Week Low	$84.38	$84.77	$99.98	$25.31	$42.64
52-Week High	$220.20	$120.27	$189.99	$141.01	$121.16
MarketRank™
Overall Score	2.2	2.5	2.0	2.1	2.3
Analysis Score	3.3	2.3	2.1	3.1	3.4
Community Score	4.7	5.0	4.9	3.3	4.9
Dividend Score	0.0	0.0	0.0	0.0	0.0
Ownership Score	2.5	2.5	2.5	3.3	3.3
Earnings & Valuation Score	0.6	2.5	0.6	0.6	0.0
Analyst Ratings
Consensus Recommendation	Buy	Buy	Hold	Hold	Buy
Consensus Price Target	$161.13	$119.46	$171.29	$67.00	$111.00
% Upside from Price Target	67.55% upside	14.73% upside	-1.09% downside	72.72% upside	84.60% upside
Trade Information
Market Cap	$7.33 billion	$9.84 billion	$10.55 billion	$5.07 billion	$5.72 billion
Beta	2.26	0.73	0.35	-1.68	1.74
Average Volume	1,641,844	862,089	502,273	1,188,193	1,020,020
Sales & Book Value
Annual Revenue	$720,000.00	$1.05 billion	$92.52 million	$76.37 million	$31.43 million
Price / Sales	10,178.13	9.41	113.99	66.34	182.10
Cashflow	N/A	$5.01 per share	N/A	N/A	N/A
Price / Cash	N/A	20.78	N/A	N/A	N/A
Book Value	$23.37 per share	$11.99 per share	$14.19 per share	$5.63 per share	$4.41 per share
Price / Book	4.12	8.68	12.20	6.89	13.63
Profitability
Net Income	$-348.86 million	$407.30 million	$-166.03 million	$-298.67 million	$-173.39 million
EPS	($5.29)	$4.16	($2.92)	($2.51)	($1.52)
Trailing P/E Ratio	18.82	27.99	N/A	N/A	N/A
Forward P/E Ratio	N/A	28.60	N/A	N/A	N/A
P/E Growth	N/A	N/A	N/A	N/A	N/A
Net Margins	49.52%	35.34%	-221.15%	-162.75%	-441.63%
Return on Equity (ROE)	24.08%	33.04%	-26.79%	-40.77%	-27.96%
Return on Assets (ROA)	21.86%	20.72%	-24.79%	-29.33%	-19.85%
Dividend
Annual Payout	N/A	N/A	N/A	N/A	N/A
Dividend Yield	N/A	N/A	N/A	N/A	N/A
Three-Year Dividend Growth	N/A	N/A	N/A	N/A	N/A
Payout Ratio	N/A	N/A	N/A	N/A	N/A
Years of Consecutive Dividend Growth	N/A	N/A	N/A	N/A	N/A
Debt
Debt-to-Equity Ratio	N/A	0.26%	N/A	N/A	N/A
Current Ratio	26.23%	5.21%	12.07%	5.91%	6.75%
Quick Ratio	26.23%	5.08%	12.07%	5.91%	6.75%
Ownership Information
Institutional Ownership Percentage	52.68%	95.99%	87.94%	58.62%	98.36%
Insider Ownership Percentage	10.70%	4.30%	1.70%	37.20%	18.58%
Miscellaneous
Employees	410	845	312	327	279
Shares Outstanding	76.20 million	94.55 million	60.90 million	130.61 million	95.19 million
Next Earnings Date	10/27/2021 (Estimated)	11/1/2021 (Confirmed)	11/4/2021 (Estimated)	11/9/2021 (Estimated)	11/4/2021 (Estimated)
Optionable	Optionable	Optionable	Optionable	Optionable	Optionable

Source	Headline
	Is Fate Therapeutics Inc. (NASDAQ: FATE) A Good Investment Now? stocksregister.com - October 16 at 1:00 PM
	San Diego biotech veterans launch novel therapeutics firm targeting cancer, other diseases sandiegouniontribune.com - October 16 at 1:46 AM
	San Diego’s Top Public Companies See Big Market Cap Gains in FY ’21 sdbj.com - October 11 at 4:07 AM
	The Business Case For Buying Fate Therapeutics Inc. (NASDAQ: FATE) Stock Now stocksregister.com - October 5 at 10:05 AM
	Fate Therapeutics Announces Presentations at the Society for Immunotherapy of Cancer 2021 ... apnews.com - October 2 at 3:43 AM
	Fate Therapeutics Inc. (FATE) Is Worth Investing In stocksregister.com - October 1 at 12:41 PM
	Fate Therapeutics Announces Presentations at the Society for Immunotherapy of Cancer 2021 Annual Meeting finance.yahoo.com - October 1 at 12:41 PM
	Stem Cell Umbilical Cord Blood Market in North America 2021 Sees Growth Due to Rising Spending Capacity and Suitable Payment Plans prnewswire.com - October 1 at 7:40 AM
	Fate Therapeutics Enters Oversold Territory (FATE) nasdaq.com - September 30 at 9:39 PM
	How Will Fate Therapeutics Inc. (NASDAQ: FATE) Perform In The Next Few Months? marketingsentinel.com - September 29 at 6:46 PM
	Fate Therapeutics (NASDAQ:FATE) Trading Down 4.9% americanbankingnews.com - September 24 at 12:18 PM
	We're Not Very Worried About Fate Therapeutics' (NASDAQ:FATE) Cash Burn Rate nasdaq.com - September 23 at 1:03 PM
	Premarket Movers: BlackBerry, Joby Aviation, Liberty Global Cl B barrons.com - September 23 at 8:02 AM
	Should This Make Fate Therapeutics Inc. (NASDAQ: FATE) Investors Worry? stocksregister.com - September 21 at 8:33 AM
	First Week of May 2022 Options Trading For Fate Therapeutics nasdaq.com - September 20 at 3:09 PM
	Press Release: Fate Therapeutics Announces -2- sharecast.com - September 15 at 9:56 AM
	Fate Therapeutics Announces Publication of FT538 Preclinical Data Demonstrating Enhanced Serial Killing and Functional Persistence without Cytokine Support finance.yahoo.com - September 15 at 9:56 AM
	Recent Poor Results Have Made This Promising Cathie Wood Pick a Bargain finance.yahoo.com - September 14 at 6:38 PM
	Fate Therapeutics Inc. (FATE) Stock Behavior Isn’t As Predictable As You Think stocksregister.com - September 11 at 5:09 PM
	Zillow – 2 Stocks in Cathie Wood’s ARK innovation Fund Wall Street Predicts Will Rally by 40% By StockNews fintechzoom.com - September 9 at 10:24 PM
	2 Stocks in Cathie Wood’s ARK innovation Fund Wall Street Predicts Will Rally by 40% stocknews.com - September 9 at 5:24 PM
	Fate Therapeutics Inc. (NASDAQ:FATE) Forecast To Rise 33.29% To Reach Consensus Target Price marketingsentinel.com - September 8 at 5:38 PM
	What Will Fate Therapeutics Inc. (NASDAQ: FATE) Be Like In 2021 stocksregister.com - September 4 at 4:20 PM
	Why Is Fate Therapeutics (FATE) Down 21% Since Last Earnings Report? finance.yahoo.com - September 3 at 5:55 PM
	Synthetic Biology Engineers the Next Genomic Revolution genengnews.com - September 1 at 5:24 PM

Date	Company	Brokerage	Action
10/14/2021	Neurocrine Biosciences	Morgan Stanley	Downgrade
10/13/2021	CRISPR Therapeutics	Chardan Capital	Reiterated Rating
10/13/2021	CRISPR Therapeutics	Stifel Nicolaus	Lower Price Target
10/13/2021	CRISPR Therapeutics	William Blair	Reiterated Rating
10/6/2021	Acceleron Pharma	Jefferies Financial Group	Initiated Coverage
10/4/2021	Acceleron Pharma	Raymond James	Downgrade
10/1/2021	Acceleron Pharma	Morgan Stanley	Reiterated Rating
10/1/2021	Acceleron Pharma	Barclays	Downgrade
9/30/2021	Neurocrine Biosciences	HC Wainwright	Reiterated Rating
9/30/2021	Acceleron Pharma	Cowen	Downgrade
9/30/2021	Acceleron Pharma	Morgan Stanley	Downgrade
9/30/2021	Acceleron Pharma	HC Wainwright	Downgrade
9/30/2021	Acceleron Pharma	Piper Sandler	Downgrade
9/30/2021	Acceleron Pharma	SVB Leerink	Boost Price Target
9/27/2021	Acceleron Pharma	Royal Bank of Canada	Boost Price Target
9/22/2021	Neurocrine Biosciences	Needham & Company LLC	Initiated Coverage
9/22/2021	Vir Biotechnology	The Goldman Sachs Group	Downgrade
8/26/2021	Fate Therapeutics	Morgan Stanley	Initiated Coverage
8/23/2021	Fate Therapeutics	HC Wainwright	Reiterated Rating
8/16/2021	CRISPR Therapeutics	Canaccord Genuity	Boost Price Target
8/6/2021	Neurocrine Biosciences	Canaccord Genuity	Downgrade
8/6/2021	Vir Biotechnology	Barclays	Lower Price Target
8/5/2021	Acceleron Pharma	Piper Sandler	Boost Price Target
8/5/2021	Fate Therapeutics	HC Wainwright	Boost Price Target
8/5/2021	Fate Therapeutics	SVB Leerink	Lower Price Target
8/4/2021	Neurocrine Biosciences	Morgan Stanley	Lower Price Target
7/30/2021	CRISPR Therapeutics	Chardan Capital	Lower Price Target
7/19/2021	Acceleron Pharma	Wolfe Research	Initiated Coverage
7/16/2021	Neurocrine Biosciences	HC Wainwright	Reiterated Rating
7/9/2021	Fate Therapeutics	Stifel Nicolaus	Reiterated Rating
7/7/2021	CRISPR Therapeutics	Chardan Capital	Reiterated Rating
6/28/2021	Vir Biotechnology	Needham & Company LLC	Reiterated Rating
6/27/2021	Acceleron Pharma	SVB Leerink	Reiterated Rating
6/24/2021	Acceleron Pharma	Oppenheimer	Boost Price Target
6/15/2021	Acceleron Pharma	SVB Leerink	Reiterated Rating
6/14/2021	CRISPR Therapeutics	Citigroup	Upgrade
6/7/2021	Fate Therapeutics	HC Wainwright	Upgrade
5/18/2021	Neurocrine Biosciences	The Goldman Sachs Group	Initiated Coverage
5/14/2021	Fate Therapeutics	Wedbush	Downgrade
5/13/2021	CRISPR Therapeutics	Evercore ISI	Upgrade
5/7/2021	Fate Therapeutics	Wedbush	Upgrade
5/6/2021	Neurocrine Biosciences	Wedbush	Lower Price Target
5/6/2021	Neurocrine Biosciences	Oppenheimer	Lower Price Target
5/6/2021	Neurocrine Biosciences	Morgan Stanley	Lower Price Target
5/6/2021	Neurocrine Biosciences	SVB Leerink	Lower Price Target
5/6/2021	Neurocrine Biosciences	Barclays	Upgrade
5/3/2021	Neurocrine Biosciences	Mizuho	Lower Price Target
4/26/2021	Neurocrine Biosciences	Mizuho	Lower Price Target
4/26/2021	Fate Therapeutics	Jefferies Financial Group	Initiated Coverage
4/21/2021	CRISPR Therapeutics	Barclays	Boost Price Target
4/21/2021	CRISPR Therapeutics	Jefferies Financial Group	Upgrade
4/19/2021	Neurocrine Biosciences	Morgan Stanley	Boost Price Target
4/16/2021	Vir Biotechnology	Needham & Company LLC	Reiterated Rating
4/12/2021	Neurocrine Biosciences	Wedbush	Lower Price Target
3/29/2021	Acceleron Pharma	The Goldman Sachs Group	Reiterated Rating
3/29/2021	Acceleron Pharma	SVB Leerink	Reiterated Rating
3/23/2021	Acceleron Pharma	SVB Leerink	Downgrade
3/22/2021	Acceleron Pharma	The Goldman Sachs Group	Reiterated Rating
3/12/2021	Fate Therapeutics	SVB Leerink	Boost Price Target
3/11/2021	Acceleron Pharma	Wolfe Research	Initiated Coverage
3/8/2021	Vir Biotechnology	HC Wainwright	Boost Price Target
3/8/2021	Vir Biotechnology	Needham & Company LLC	Boost Price Target
3/5/2021	Neurocrine Biosciences	Robert W. Baird	Reiterated Rating
3/4/2021	CRISPR Therapeutics	JMP Securities	Initiated Coverage
3/4/2021	Fate Therapeutics	Wedbush	Reiterated Rating
3/4/2021	Fate Therapeutics	Wells Fargo & Company	Boost Price Target
3/3/2021	Vir Biotechnology	The Goldman Sachs Group	Boost Price Target
3/2/2021	Vir Biotechnology	Needham & Company LLC	Boost Price Target
3/1/2021	CRISPR Therapeutics	Barclays	Boost Price Target
3/1/2021	Acceleron Pharma	Citigroup	Boost Price Target
2/28/2021	CRISPR Therapeutics	Barclays	Reiterated Rating
2/26/2021	Acceleron Pharma	Piper Sandler	Boost Price Target
2/26/2021	Acceleron Pharma	Morgan Stanley	Boost Price Target
2/26/2021	Acceleron Pharma	SVB Leerink	Boost Price Target
2/26/2021	Fate Therapeutics	Truist	Boost Price Target
2/26/2021	Fate Therapeutics	Bank of America	Initiated Coverage
2/26/2021	Fate Therapeutics	Wedbush	Downgrade
2/25/2021	Vir Biotechnology	Barclays	Boost Price Target
2/25/2021	Fate Therapeutics	Roth Capital	Boost Price Target
2/25/2021	Fate Therapeutics	Cantor Fitzgerald	Boost Price Target
2/25/2021	Fate Therapeutics	Mizuho	Boost Price Target
2/17/2021	CRISPR Therapeutics	The Goldman Sachs Group	Lower Price Target
2/17/2021	CRISPR Therapeutics	Oppenheimer	Boost Price Target
2/17/2021	CRISPR Therapeutics	Chardan Capital	Boost Price Target
2/17/2021	CRISPR Therapeutics	Needham & Company LLC	Reiterated Rating
2/17/2021	Fate Therapeutics	Piper Sandler	Boost Price Target
2/11/2021	Fate Therapeutics	Citigroup	Downgrade
2/5/2021	Neurocrine Biosciences	Mizuho	Boost Price Target
2/1/2021	Neurocrine Biosciences	Raymond James	Initiated Coverage
1/29/2021	Acceleron Pharma	JPMorgan Chase & Co.	Boost Price Target
1/27/2021	Vir Biotechnology	JPMorgan Chase & Co.	Downgrade
1/27/2021	Fate Therapeutics	HC Wainwright	Reiterated Rating
1/26/2021	Neurocrine Biosciences	William Blair	Reiterated Rating
1/25/2021	Fate Therapeutics	BMO Capital Markets	Boost Price Target
1/21/2021	Neurocrine Biosciences	Canaccord Genuity	Reiterated Rating
1/20/2021	Vir Biotechnology	HC Wainwright	Boost Price Target
1/19/2021	Fate Therapeutics	Oppenheimer	Reiterated Rating
1/15/2021	Fate Therapeutics	Barclays	Boost Price Target
1/12/2021	CRISPR Therapeutics	Truist	Boost Price Target
12/29/2020	Neurocrine Biosciences	Cantor Fitzgerald	Lower Price Target
12/25/2020	Vir Biotechnology	Robert W. Baird	Reiterated Rating
12/24/2020	Vir Biotechnology	Robert W. Baird	Reiterated Rating
12/21/2020	Fate Therapeutics	Stifel Nicolaus	Boost Price Target
12/16/2020	Neurocrine Biosciences	Morgan Stanley	Lower Price Target
12/10/2020	CRISPR Therapeutics	Chardan Capital	Boost Price Target
12/10/2020	CRISPR Therapeutics	Jefferies Financial Group	Downgrade
12/10/2020	CRISPR Therapeutics	Needham & Company LLC	Boost Price Target
12/10/2020	CRISPR Therapeutics	Piper Sandler	Boost Price Target
12/7/2020	CRISPR Therapeutics	Stifel Nicolaus	Boost Price Target
12/7/2020	CRISPR Therapeutics	Canaccord Genuity	Boost Price Target
12/7/2020	CRISPR Therapeutics	Oppenheimer	Boost Price Target
12/7/2020	Neurocrine Biosciences	Wedbush	Lower Price Target
11/12/2020	Neurocrine Biosciences	Canaccord Genuity	Lower Price Target
10/7/2020	Vir Biotechnology	HC Wainwright	Boost Price Target
10/5/2020	Vir Biotechnology	Bank of America	Initiated Coverage
9/21/2020	Vir Biotechnology	HC Wainwright	Boost Price Target
9/14/2020	Vir Biotechnology	The Goldman Sachs Group	Upgrade
9/11/2020	Vir Biotechnology	JPMorgan Chase & Co.	Upgrade
8/31/2020	Vir Biotechnology	The Goldman Sachs Group	Boost Price Target
8/24/2020	Vir Biotechnology	HC Wainwright	Reiterated Rating
8/20/2020	Vir Biotechnology	Needham & Company LLC	Initiated Coverage
8/12/2020	Vir Biotechnology	Barclays	Boost Price Target
5/13/2020	Vir Biotechnology	Barclays	Boost Price Target
3/29/2020	Vir Biotechnology	Barclays	Reiterated Rating
3/27/2020	Vir Biotechnology	Robert W. Baird	Boost Price Target

(Data available from 10/18/2018 forward. View 10+ years of historical ratings with our analyst ratings screener.)

30 Days of MarketBeat All Access for $1.00

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your Risk-Free Trial Subscription Here

Your Ultimate Investing Toolkit

Just $1.00 for your first month.

Compare Stocks

30 Days of MarketBeat All Access for $1.00

Resources

Premium Research Tools

Market Data and Calendars

Investing Education and Resources